Latest news
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - BitgetBitget · Sun, 09 Aug 2026 04:41:47 GMTUAB awards grants to study atherosclerosis advancement and MYC-driven cancers - Alabama Political ReporterAlabama Political Reporter · Wed, 05 Aug 2026 12:51:00 GMTCancer treatment makes tumor vulnerable to immune system attack, research finds - The Jerusalem PostThe Jerusalem Post · Wed, 05 Aug 2026 11:47:00 GMTSilexion Therapeutics Reports New Positive Preclinical - GlobeNewswireGlobeNewswire · Tue, 04 Aug 2026 13:15:00 GMTSilexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock TitanStock Titan · Tue, 04 Aug 2026 13:15:00 GMTJohnson & Johnson and Firefly: Targeting KRAS-Driven Cancers - Healthcare DigitalHealthcare Digital · Fri, 31 Jul 2026 07:00:00 GMT